Sign inJoin waitlistJoin the waitlist

Eric Knoche

Assistant Professor of Medicine · Washington University/B-JH/SLCH Consortium

Credentials: · ·

History

Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2009–2012
Internal Medicine
Barnes-Jewish Hospital
2006–2009
Washington University School of Medicine
2002–2006
Davidson College, Davidson, NC
1998–2002

Research

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Review · Cancers · 2021 · 61 citations
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
Prostate Cancer and Prostatic Diseases · 2023 · 33 citations
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National…
Clinical and Translational Radiation Oncology · 2019 · 18 citations

Russell Pachynski
5 papers
Martin Schoen
4 papers · 4 as a fellow
Benjamin Fischer-Valuck
3 papers · 2 as a resident
BB
Brian Baumann
3 papers
BR
Bruce Roth
3 papers
Eric Kim
3 papers · 2 as a fellow
Hiram Gay
3 papers
Jeff Michalski
3 papers
John Christodouleas
3 papers
MR
Melissa Reimers
3 papers
VA
Vivek Arora
3 papers
Amy Zhou
2 papers · 2 as a fellow

Clinical trials

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2025–2034
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027